To compare the diagnostic criteria for Alzheimer’s disease proposed by the Alzheimer’s Association (AA) and the International Working Group (IWG) in 2024, highlighting the implications of their differences.
Key Findings:
Both AA and IWG criteria emphasize the use of biomarkers for diagnosing Alzheimer’s disease, which is crucial for clinical practice.
Core biomarkers include amyloid and tau PET scans, and CSF measurements of amyloid-β42 and phosphorylated tau, which are essential for accurate diagnosis.
AA considers cognitively unimpaired individuals with Alzheimer’s pathology as having the disease, while IWG views them as at risk of developing the disease, impacting treatment approaches.
The IWG recognizes presymptomatic disease in cases of advanced tau pathology or penetrant genetic variants, which could influence patient management.
Interpretation:
The differing interpretations of 'disease' and 'pathology' between AA and IWG lead to distinct diagnostic approaches, with significant implications for clinical practice and patient management.
Limitations:
Further research is needed on cognitively unimpaired individuals with Alzheimer’s pathology to improve risk prediction and inform clinical guidelines.
The debate on definitions may hinder consensus on diagnostic criteria, potentially affecting research funding and focus.
Conclusion:
Despite differences in interpretation, both AA and IWG criteria align on the importance of biomarker testing for symptomatic individuals, marking a significant advancement in Alzheimer’s disease diagnosis, which could shape future research and treatment strategies.
